Oral delivery of diabetes peptides — Comparing standard formulations incorporating functional excipients and nanotechnologies in the translational context

Advanced Drug Delivery Reviews

Volumn 106, Issue , 2016, Pages 196-222

  Lakkireddy, Harivardhan Reddy ^a   Urmann, Matthias ^b   Besenius, Melissa ^b   Werner, Ulrich ^b   Haack, Torsten ^b   Brun, Priscilla ^a   Alié, Jean ^a   Illel, Brigitte ^a   Hortala, Laurent ^a   Vogel, Rachel ^a   Bazile, Didier ^a  

^a SANOFI   (France)

^b Research and Development   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; DRUG DOSAGE; DRUG PRODUCTS; NANOTECHNOLOGY; PEPTIDES; TARGETED DRUG DELIVERY;

INTESTINAL BARRIERS; NANO-CARRIERS; ORAL BIOAVAILABILITIES; ORAL DELIVERY; ORAL DOSAGE; PHYSICO-CHEMICALS;

CONTROLLED DRUG DELIVERY;

AMYLIN; CHITOSAN NANOPARTICLE; EXCIPIENT; EXENDIN 4; GHRELIN; GHRELIN ANTAGONIST; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HORMONE ANTAGONIST; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LIPOSOME; LIRAGLUTIDE; NANOCARRIER; PEPTIDE YY; PEPTIDE YY [3-36]; PLACEBO; PRAMLINTIDE; RECOMBINANT HUMAN INSULIN; SEMAGLUTIDE; SILICA NANOPARTICLE; SOLID LIPID NANOPARTICLE; UNCLASSIFIED DRUG; PEPTIDE;

BINDING AFFINITY; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; DRUG BIOAVAILABILITY; DRUG DIFFUSION; DRUG DOSAGE FORM; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TARGETING; ENTERIC COATED TABLET; GLUCOSE HOMEOSTASIS; GLYCEMIC CONTROL; HORMONE ACTION; HUMAN; HYDROPHILICITY; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE MUCOSA PERMEABILITY; LIPOSOMAL DELIVERY; MICROEMULSION; MUCOADHESION; NANOTECHNOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PERMEABILITY BARRIER; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ANIMAL; CHEMISTRY; DRUG DELIVERY SYSTEM; METABOLISM; NANOMEDICINE; ORAL DRUG ADMINISTRATION; TRANSLATIONAL RESEARCH;

ADMINISTRATION, ORAL; ANIMALS; DIABETES MELLITUS; DRUG DELIVERY SYSTEMS; EXCIPIENTS; HUMANS; NANOMEDICINE; PEPTIDES; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84961909561     PISSN: 0169409X     EISSN: 18728294     Source Type: Journal    
DOI: 10.1016/j.addr.2016.02.011     Document Type: Review

References (222)

1. [1] Craik, D., Fairlie, D., Liras, S., The future of peptide-based drugs. Chem. Biol. Drug Des. 81 (2013), 136–147.
2. [2] Horton, E., Defining the role of basal and prandial insulin for optimal glycemic control. J. Am. Coll. Cardiol. 53 (2009), S21–S27.
3. [3] Sorli, C., New developments in insulin therapy for type 2 diabetes. Am. J. Med. 127 (2014), S39–S48.
4. [4] Tibaldi, J., Evolution of insulin: from human to analog. Am. J. Med. 127 (2014), S25–S38.
5. [5] Lorenz, M., Evers, A., Wagner, M., Recent progress and future options in the development of GLP-1 receptor agonists for the treatment of diabesity. Bioorg. Med. Chem. Lett. 23 (2013), 4011–4018.
6. [6] Lund, A., Knop, F., Vilsbøll, T., Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. Eur. J. Int. Med. 25 (2014), 407–414.
7. [7] Smart, A., Gaisford, S., Basit, A., Oral peptide and protein delivery: intestinal obstacles and commercial prospects. Expert Opin. Drug Deliv. 11:8 (2014), 1323–1335.
8. [8] Choonara, B., Choonara, Y., Kumar, P., Bijukumar, D., du Toit, L., Pillay, V., A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules. Biotechnol. Adv. 32 (2014), 1269–1282.
9. [9] Novo_Nordisk, https://www.novonordisk.com/bin/getPDF.1896081.pdf, (En ligne).
10. [10] Amidon, G., Lennernäs, H., Shah, V., Crison, J., A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:3 (1995), 413–420.
11. [11] Shen, L., Black, E., Witkowski, E., Lencer, W., Guerriero, V., Schneeberger, E., Turner, J., Myosin light chain phosphorylation regulates barrier function by remodeling tight junction structure. J. Cell Sci. 119 (2006), 2095–2106 (119, 2095-2106).
12. [12] Krug, S., Amasheh, M., Dittmann, I., Christoffel, I., Fromma, M., Sodium caprate as an enhancer of macromolecule permeation across tricellular tight junctions of intestinal cells. Biomaterials 34 (2013), 275–282.
13. [13] Taverner, A., Dondi, R., Almansour, K., Laurent, F., Owens, S.-E., Eggleston, I., Fotaki, N., Mrsny, R., Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation. J. Control. Release 210 (2015), 189–197.
14. [14] Brayden, D., Gleeson, J., Walsh, E., A head-to-head multi-parametric high content analysis of a series of medium chain fatty acid intestinal permeation enhancers in Caco-2 cells. Eur. J. Pharm. Biopharm. 88 (2014), 830–839.
15. [15] Gradauer, K., Nishiumi, A., Unrinin, K., Higashino, H., Kataoka, M., Pedersen, B., Buckley, S., Yamashita, S., Interaction with mixed micelles in the intestine attenuates the permeation enhancing potential of alkyl-maltosides. Mol. Pharm., 2015, 10.1021/mp500776a.
16. [16] Damge, C., Michel, C., Aprahamian, M., Couvreur, P., New approach for oral administration of insulin with polyalkylcyanoacrylate nanocapsules as drug carrier. Diabetes 37 (1988), 246–251.
17. [17] Damge, C., Pinto Reis, C., Maincent, P., Nanoparticle strategies for the oral delivery of insulin. Expert Opin. Drug Deliv. 5:1 (2008), 45–68.
18. [18] Stern, S., Hall, J., Yu, L., Wood, L., Paciotti, G., Tamarkin, L., Long, S., McNeil, S., Translational considerations for cancer nanomedicine. J. Control. Release 146 (2010), 164–174.
19. [19] Bazile, D., Nanotechnologies in drug delivery — an industrial perspective. J. Drug Delivery Sci. Technol. 24:11 (2014), 12–21.
20. [20] Aronoff, S., Berkowitz, K., Shreiner, B., Want, L., Glucose metabolism and regulation: beyond insulin and glucagon. Diabetes Spectr. 17:13 (2004), 183–190.
21. [21] Home, P.D., Plasma insulin profiles after subcutaneous injection: how close can we get to physiology in people with diabetes?. Diabetes Obes. Metab. 17 (2015), 1011–1020.
22. [22] Evans, M., Schumm-Draeger, P., Vora, J., King, A., A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. Diabetes Obes. Metab. 13 (2011), 677–684.
23. [23] Freeman, J., Insulin analog therapy: improving the match with physiologic insulin secretion. J. Am. Osteopath. Assoc. 109 (2009), 26–36.
24. [24] Morello, C., Pharmacokinetics and pharmacodynamics of insulin analogs in special populations with type 2 diabetes mellitus. Int. J. Gen. Med. 4 (2011), 827–835.
25. [25] Fonte, P., Araújo, F., Reis, S., Sarmento, B., Oral insulin delivery: how far are we?. J. Diabetes Sci. Technol. 7:12 (2013), 520–531.
26. [26] Matteucci, E., Giampietro, O., Covolan, V., Giustarini, D., Fanti, P., Rossi, R., Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery. Drug Des. Dev. Ther. 9 (2015), 3109–3118.
27. [27] Elsayed, A., Oral delivery of insulin: novel approaches. Sezer, A.D., (eds.) Recent Advances Novel Drug Carrier Systems InTech publisher, 2012.
28. [28] Zijlstra, E., Heinemann, L., Plum-Mörschel, L., Oral insulin reloaded: a structured approach. J. Diabetes Sci. Technol. 8:13 (2014), 458–465.
29. [29] King, A., The use of animal models in diabetes research. Br. J. Pharmacol. 166 (2012), 877–894.
30. [30] Holst, J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
31. [31] Kim, W., Egan, J., The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol. Rev. 60:14 (2008), 470–512.
32. [32] Drucker, D., Philippe, J., Mojsov, S., Chick, W., Habener, J., Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc. Natl. Acad. Sci. 84 (1987), 3434–3438.
33. [33] Farilla, L., Bulotta, A., Hirshberg, B., Li Calzi, S., Khoury, N., Noushmehr, H., Bertolotto, C., Di Mario, U., Harlan, D., Perfetti, R., Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003), 5149–5158.
34. [34] Prasad-Reddy, L., Isaacs, D., A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context 4 (2015), 1–19.
35. [35] Villsboll, T., Agerso, H.K.T., Holst, J., Similar elimination rates of glucagon-like peptide-1 in obese type 2 diabetic patients and healthy subjects. J. Clin. Endocrinol. Metab. 88:11 (2003), 220–224.
36. [36] Eng, J., Kleinman, W., Singh, L., Singh, G., Raufman, J.-P., Isolation and characterizationo f exendin-4, an exendin-3 analogue from heloderma suspecturn venom. J. Biol. Chem. 267:111 (1992), 7402–7405.
37. [37] Drucker, D., Dritselis, A., Kirkpatrick, P., Liraglutide. Nat. Rev. Drug Discov. 9 (2010), 267–268.
38. [38] Werner, U., Haschke, G., Herling, A., Kramer, W., Pharmacological profile of lixisenatide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Regul. Pept. 164 (2010), 58–64.
39. [39] Kratz, F., A clinical update of using albumin as a drug vehicle — a commentary. J. Control. Release 190 (2014), 331–336.
40. [40] Lau, J.B.P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., Madsen, K., Knudsen, L.-B., McGuire, J., Steensgaard, D., Strauss, H., Gram, D., Knudsen, S., Nielsen, F., Thygesen, P., Reedtz-Runge, S., Kruse, T., Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J. Med. Chem. 58 (2015), 7370–7380.
41. [41] Blair, H., Keating, G., Albiglutide: a review of its use in patients with type 2 diabetes mellitus. Drugs 75 (2015), 651–663.
42. [42] Edwards, K., Minze, M., Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes. Core Evid. 10 (2015), 11–21.
43. [43] Novo_Nordisk, https://www.novonordisk.com/bin/getPDF.1947638.pdf, (En ligne).
44. [44] Ekblad, E., Sundler, F., Distribution of pancreatic polypeptide and peptide YY. Peptides 23 (2002), 251–261.
45. [45] Abbott, C., Small, C., Kennedy, A., Neary, N., Sajedi, A., Ghatei, M., Bloom, S., Blockade of the neuropeptide Y Y2 receptor with the specific antagonist BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3–36) on food intake. Brain Res. 1043 (2005), 139–144.
46. [46] Adrian, T., Ferri, G.-L., Bacarese-Hamilton, A., Fuessl, H., Polak, J., Bloom, S., Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology 89 (1985), 1070–1077.
47. [47] Tschöp, M., Smiley, D., Heiman, M., Ghrelin induces adiposity in rodents. Nature 407 (2000), 908–913.
48. [48] Cummings, D., Weigle, D., Frayo, R., Breen, P., Ma, M., Dellinger, E., Purnell, J., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N. Engl. J. Med. 346:121 (2002), 1623–1630.
49. [49] Nakazato, M., Murakami, N., Date, Y., Kojima, M., Matsuo, H., Kangawa, K., Matsukura, S., A role for ghrelin in the central regulation of feeding. Nature 409 (2001), 194–198.
50. [50] Pittner, R., Albrandt, K., Beaumont, K., Geata, L., Koda, J., Moore, C., Rittenhouse, J., Rink, T., Molecular physiology of amylin. J. Cell. Biochem. 55S (1994), 19–28.
51. [51] Morley, J., Flood, J., Horowitz, M., Morley, P., Walter, M., Modulation of food intake by periperally administered amylin. Am. J. Phys. 267 (1994), R178–R184.
52. [52] Cooper, G., Amylin and insulin co-replacement therapy for insulin-dependent (type i) diabetes mellitus. Med. Hypotheses 36 (1991), 284–288.
53. [53] Roth, J., Roland, B., Cole, R., Trevaskis, J., Weyer, C., Koda, J., Anderson, C., Parkes, D., Baron, A., Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies. PNAS 105:120 (2008), 7257–7262.
54. [54] Whitehouse, F., Kruger, D., Fineman, M., Shen, L., Ruggles, J., Maggs, D., Weyer, C., Kolterman, O., A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes. Diabetes Care 25 (2002), 724–730.
55. [55] Chen, H., Roth, J., Schroeder, B., Weyer, C., Role of islet-, gut-, and adipocyte-derived hormones in the central role of islet-, gut-, and adipocyte-derived hormones in the central neurohormonal approach to obesity pharmacotherapy. Curr. Diabetes Rev. 4 (2008), 79–91.
56. [56] Murlin, J.R., Gibbs, C.B.F., Romansky, M.J., Steinhausen, T.B., Truax, F.L., Effectiveness of per-oral insulin in human diabetes. J. Clin. Invest. 19 (1940), 709–722.
57. [57] Crane, C., Path, M., Luntz, G., Absorption of insulin from the human small intestine. Diabetes 17:110 (1968), 625–627.
58. [58] Parks, D., Jacobson, E., Physiology of the splanchnic circulation. Arch. Intern. Med. 145 (1985), 1278–1281.
59. [59] Leone-Bay, A., McInnes, C., Wang, N., DeMorin, F., Achan, D., Lercara, C., Sarubbi, D., Haas, S., Press, J., Barantsevich, E., O'Broin, B., Milstein, S., Paton, D., Microsphere formation in a series of derivatized a-amino acids: properties molecular modeling, and oral delivery of salmon calcitonin. J. Med. Chem. 38 (1995), 4257–4262.
60. [60] Leone-Bay, A., Paton, D., Weidner, J., The development of delivery agent that facilitate the oral absorption of macromolecular drugs. Med. Res. Rev. 20:12 (2000), 169–186.
61. [61] Malkov, D., Angelo, R., Wang, H.-Z., Flanders, E., Tang, H., Gomez-Orellana, I., Oral delivery of insulin with the Eligen® technology: mechanistic studies. Curr. Drug Deliv. 2 (2005), 191–197.
62. [62] Hoffman, A., Qadri, B., Eligen insulin — a system for the oral delivery of insulin for diabetes. IDrugs 11:16 (2008), 433–441.
63. [63] Chen, M.-C., Sonaje, K., Chen, K., Sung, H.-W., A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32 (2011), 9826–9838.
64. [64] Aguirre, T.A., Teijeiro-Osorio, D., Rosa, M., Alonso, M.-J., Brayden, D.J., Current status of selected oral peptide technologies in advanced preclinical development and in clinical trials. (in this volume), 2016.
65. [65] Arbit, E., Kidron, M., Oral insulin: the rationale for this approach and current developments. J. Diabetes Sci. Technol. 3:13 (2009), 562–567.
66. [66] Lindmark, T., Schipper, N., Lazorova, L., de Boer, A., Artursson, P., Absorption enhancement in intestinal epithelial Caco-2 monolayers by sodium caprate: assessment of molecular weight dependence and demonstration of transport routes. J. Drug Target. 5:13 (1997), 215–223.
67. [67] Baluom, M., Friedman, M., Rubinstein, A., The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. Int. J. Pharm. 176 (1998), 21–30.
68. [68] Patel, H., Ryman, B., Oral administration of insulin by encapsulation within liposomes. FEBS Lett. 62:11 (1976), 60–63.
69. [69] Dapergolas, G., Gregoriadis, G., Hypoglycemic effect of liposome-entrapped insulin administered intragastrically into rats. Lancet 2 (1976), 824–827.
70. [70] Hashimoto, A., Kawada, J., Effects of oral administration of positively charged insulin liposomes on alloxan diabetic rats: preliminary study. Endocrinol. Jpn. 26:13 (1979), 337–344.
71. [71] Arrieta-Molero, J., Aleck, K., Sinha, M., Brownscheidle, C., Shapiro, L., Sperling, M., Orally administered liposome-entrapped insulin in diabetic animals. Horm. Res. 16 (1982), 249–256.
72. [72] Choudhari, K., Labhasetwar, V., Dorle, A., Liposomes as a carrier for oral administration of insulin: effects of formulation factors. J. Microencapsul. 11:13 (1994), 319–325.
73. [73] Kisel, M., Kulik, L., Tsybovsky, I., Vlasov, A., Vorob'yov, M., Kholodova, E., Zabarovskaya, Z., Liposomes with phosphatidylethanol as a carrier for oral delivery of insulin: studies in the rat. Int. J. Pharm. 216 (2001), 105–114.
74. [74] Wiessner, J., Mar, H., Baskin, D., Hwang, K., Peptidecarrier interaction: induction of liposome fusion and aggregation by insulin. J. Pharm. Sci. 75:13 (1986), 259–263.
75. [75] Patel, H., Stevenson, R., Parson, J., Ryman, B., Use of liposomes to aid intestinal absorption of entrapped insulin in normal and diabetic dogs. Biochim. Biophys. Acta 716 (1982), 188–193.
76. [76] Niu, M., Lu, Y., Hovgaard, L., Wu, W., Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation. Int. J. Nanomedicine 6 (2011), 1155–1166.
77. [77] Niu, M., Lua, Y., Hovgaard, L., Guan, P., Tan, Y., Lian, R., Qi, J., Wu, W., Hypoglycemic activity and oral bioavailability of insulin-loaded liposomes containing bile salts in rats: the effect of cholate type, particle size and administered dose. Eur. J. Pharm. Biopharm. 81 (2012), 265–272.
78. [78] Hu, S., Niu, M., Hu, F., Lu, Y., Qi, J., Yin, Z., Wu, W., Integrity and stability of oral liposomes containing bile salts studied in simulated and ex vivo gastrointestinal media. Int. J. Pharm. 441 (2013), 693–700.
79. [79] Niu, M., Tan, Y., Guan, P., Hovgaard, L., Lu, Y., Qi, J., Lian, R., Li, X., Wu, W., Enhanced oral absorption of insulin-loaded liposomes containing bile salts: a mechanistic study. Int. J. Pharm. 460 (2014), 119–130.
80. [80] Geho, W., Geho, H., Lau, J., Gana, T., Hepatic-directed vesicle insulin: a review of formulation development and preclinical evaluation. J. Diabetes Sci. Technol. 3:16 (2009), 1451–1459.
81. [81] Michel, C., Aprahamian, M., Defontaine, L., Couvreur, P., Damgé, C., The effect of site of administration in the gastrointestinal tract on the absorption of insulin from nanocapsules in diabetic rats. J. Pharm. Pharmacol. 43 (1991), 1–5.
82. [82] Damge, C., Vranckx, H., Balschmidt, P., Couvreur, P., Poly(alkyl cyanoacrylate) nanospheres for oral administration of insulin. J. Pharm. Sci. 86:112 (1997), 1403–1409.
83. [83] Mesiha, M., Sidhom, M., Fasipe, B., Oral and subcutaneous absorption of insulin poly(isobutylcyanoacrylate) nanoparticles. Int. J. Pharm. 288 (2005), 289–293.
84. [84] Radwan, M., Aboul-Enein, H., The effect of oral absorption enhancers on the in vivo performance of insulin-loaded poly(ethylcyanoacrylate) nanospheres in diabetic rats. J. Microencapsul. 19:12 (2002), 225–235.
85. [85] Radwan, M., Enhancement of absorption of insulin-loaded polyisobutylcyanoacrylate nanospheres by sodium cholate after oral and subcutaneous administration in diabetic rats. Drug Dev. Ind. Pharm. 27:19 (2001), 981–989.
86. [86] Yang, J., Sun, H., Song, C., Preparation, characterization and in vivo evaluation of pH-sensitive oral insulin-loaded poly(lactic-co-glycolicacid) nanoparticles. Diabetes Obes. Metab., 358–364, 2012, 14.
87. [87] Sun, S., Liang, N., Piao, H., Yamamoto, H., Kawashim, Y., Cui, F., Insulin-SO (sodium oleate) complex-loaded PLGA nanoparticles: formulation, characterization and in vivo evaluation. J. Microencapsul. 27:16 (2010), 471–478.
88. [88] Wu, Z., Zhou, L., Guo, X., Jiang, W., Linga, L., Qian, Y., Luo, K., HP55-coated capsule containing PLGA/RS nanoparticles for oral delivery of insulin. Int. J. Pharm. 425 (2012), 1–8.
89. [89] Uchida, T., Yagi, A., Oda, Y., Nakada, Y., Goto, S., Instability of bovine insulin in poly(lactide-co-glycolide) (PLGA) microspheres. Chem. Pharm. Bull. 44:11 (1996), 235–236.
90. [90] Ibrahim, M., Ismail, A., Fetouh, M., Gopferich, A., Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release 106 (2005), 241–252.
91. [91] Sharma, G., van der Walle, C., Ravi Kumar, M., Antacid co-encapsulated polyester nanoparticles for peroral delivery of insulin: Development, pharmacokinetics, biodistribution and pharmacodynamics. Int. J. Pharm. 440 (2013), 99–110.
92. [92] Lin, Y.-H., Mi, F.-L., Chen, C.-T., Chang, W.-C., Peng, S.-F., Liang, H.-F., Sung, H.-W., Preparation and characterization of nanoparticles shelled with chitosan for oral insulin delivery. Biomacromolecules 8 (2007), 146–152.
93. [93] Sung, H.-W., Sonaje, K., Liao, Z., Hsu, L.-W., Chuang, E.-Y., pH-responsive nanoparticles shelled with chitosan for oral delivery of insulin: from mechanism to therapeutic applications. Acc. Chem. Res. 45:14 (2012), 619–629.
94. [94] Sonaje, K., Lin, Y.-H., Juang, J.-H., Wey, S.-P., Chen, C.-T., Sung, H.-W., In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 30 (2009), 2329–2339.
95. [95] Lin, Y.-H., Chung, C.-K., Chen, C.-T., Liang, H.-F., Chen, S.-C., Sung, H.-W., Preparation of nanoparticles composed of chitosan/poly-g-glutamic acid and evaluation of their permeability through Caco-2 cells. Biomacromolecules 6 (2005), 1104–1112.
96. [96] Yeh, T.-H., Hsu, L.-W., Tseng, M., Lee, P.-L., Sonaje, K., Ho, Y.-C., Sung, H.-W., Mechanism and consequence of chitosan-mediated reversible epithelial tight junction opening. Biomaterials 32 (2011), 6164–6173.
97. [97] Sonaje, K., Lin, K.-J., Wey, S.-P., Lin, C.-K., Yeh, T.-H., Nguyen, H.-N., Hsu, C.-W., Yen, T.-C., Juang, J.-H., Sung, H.-W., Biodistribution, pharmacodynamics and pharmacokinetics of insulin analogues in a rat model: oral delivery using pH-responsive nanoparticles vs. subcutaneous injection. Biomaterials 31 (2010), 6849–6858.
98. [98] Chuang, E.-Y., Lin, K.-J., Su, F.-Y., Chen, H.-L., Maiti, B., Ho, Y.-C., Yen, T.-C., Panda, N., Sung, H.-W., Calcium depletion-mediated protease inhibition and apical-junctional-complex disassembly via an EGTA-conjugated carrier for oral insulin delivery. J. Control. Release 169 (2013), 296–305.
99. [99] Su, F.-Y., Lin, K.-J., Sonaje, K., Wey, S.-P., Yen, T.-C., Ho, Y.-C., Panda, N., Chuang, E.-Y., Maiti, B., Sung, H.-W., Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 33 (2012), 2801–2811.
100. [100] Bernkop-Schnurch, A., The use of inhibitory agents to overcome the enzymatic barrier to perorally administered therapeutic peptides and proteins. J. Control. Release 52 (1998), 1–16.
101. [101] Sonaje, K., Chen, Y.-J., Chen, H.-L., Wey, S.-P., Juang, J.-H., Nguyen, H.-N., Hsu, C.-W., Lin, K., Sung, H.-W., Enteric-coated capsules filled with freeze-dried chitosan/poly(g-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 31 (2010), 3384–3394.
102. [102] Sarmento, B., Martins, S., Ferreira, D., Souto, E., Oral insulin delivery by means of solid lipid nanoparticles. Int. J. Nanomedicine 2:14 (2007), 743–749.
103. [103] Yang, R., Gao, R., Li, F., He, H., Tang, X., The influence of lipid characteristics on the formation, in vitro release, and in vivo absorption of protein-loaded SLN prepared by the double emulsion process. Drug Dev. Ind. Pharm. 37:2 (2011), 139–148.
104. [104] Yang, R., Gao, R.-C., Cai, C.-F., Xu, H., Li, F., He, H.-B., Tang, X., Preparation of gel-core-solid lipid nanoparticle: a novel way to improve the encapsulation of protein and peptide. Chem. Pharm. Bull. 58:9 (2010), 1195–11202.
105. [105] Zhang, Z.-H., Zhang, Y.-L., Zhou, J.-P., Lv, H.-X., Solid lipid nanoparticles modified with stearic acid–octaarginine for oral administration of insulin. Int. J. Nanomedicine 7 (2012), 3333–3339.
106. [106] Mahkam, M., Hosseinzadeh, F., Galehassadi, M., Preparation of ionic liquid functionalized silica nanoparticles for oral drug delivery. J. Biomater. Nanobiotechnol. 3 (2012), 391–395.
107. [107] Andreani, T., de Souza, A.-L., Kiill, C., Lorenzón, E., Fangueiro, J., Calpena, A., Chaud, M., Garcia, M., Gremião, M., Silva, A., Souto, E., Preparation and characterization of PEG-coated silica nanoparticles for oral insulin delivery. Int. J. Pharm. 473 (2014), 627–635.
108. [108] Jain, R., Huang, X., Das, S., Silva, R., Ivanova, V., Minko, T., Asefa, T., Functionalized mesoporous silica nanoparticles for glucose- and pH stimulated release of insulin. Z. Anorg. Allg. Chem. 640:1(3-4) (2014), 616–623.
109. [109] Lee, J.-A., Kim, M.-K., Paek, H.-J., Kim, Y.-R., Kim, M.-K., Lee, J.-K., Jeong, J., Choi, S.-J., Tissue distribution and excretion kinetics of orally administered silica nanoparticles in rats. Int. J. Nanomedicine 9:Suppl. 2 (2014), 251–260.
110. [110] Vol, A., Gribova, O., Methods and Composition for Oral Administration of Insulin. (US Brevet 0278922 A1), 2010.
111. [111] Vol, A., Gribova, O., Matric Carrier Compositions, Methods and Uses. (US Brevet 0,100,216 A1), 2012.
112. [112] Vol, A., Gribova, O., Methods and Compositions for Oral Administration of Protein and Peptide Therapeutic Agents. (US Brevet 0,297,245 A1), 2010.
113. [113] Zhao, X., Shan, S., Zu, Y., Zhang, Y., Wang, W., Wang, K., Sui, X., Li, R., Preparation, characterization, and evaluation in vivo of Ins-SiO2-HP55 (insulin-loaded silica coating HP55) for oral delivery of insulin. Int. J. Pharm. 454 (2013), 278–284.
114. [114] Ramachandran, R., Paul, W., Sharma, C., Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery. J. Biomed. Mater. Res. B Appl. Biomater. 88B (2008), 41–48.
115. [115] Ganeshkumar, M., Ponrasu, T., Sathishkumar, M., Suguna, L., Preparation of amphiphilic hollow carbon nanosphere loaded insulin for oral delivery. Colloids Surf. B: Biointerfaces 103 (2013), 238–243.
116. [116] Morçöl, T., Nagappan, P., Nerenbaum, L., Mitchell, A., Bell, S., Calcium phosphate-PEG-insulin-casein (CAPIC) particles as oral delivery systems for insulin. Int. J. Pharm. 277 (2004), 91–97.
117. [117] Gibaud, S., Attivi, D., Microemulsions for oral administration and their therapeutic applications. Expert Opin. Drug Deliv. 9:18 (2012), 937–951.
118. [118] Cilek, A., Celebi, N., Tırnaksız, F., Tay, B., A lecithin-based microemulsion of rh-insulin with aprotinin for oral administration: investigation of hypoglycemic effects in non-diabetic and STZ-induced diabetic rats. Int. J. Pharm. 298 (2005), 176–185.
119. [119] Watnasirichaikul, S., Rades, T., Tucker, I., Davies, N., In-vitro release and oral bioactivity of insulin in diabetic rats using nanocapsules dispersed in biocompatible microemulsion. J. Pharm. Pharmacol. 54 (2002), 473–480.
120. [120] Graf, A., Rades, T., Hook, S., Oral insulin delivery using nanoparticles based on microemulsions with different structure-types: optimisation and in vivo evaluation. Eur. J. Pharm. Sci. 37 (2009), 53–61.
121. [121] Sharma, G., Wilson, K., van der Walle, C., Sattar, N., Petrie, J., Ravi Kumar, M., Microemulsions for oral delivery of insulin: design, development and evaluation in streptozotocin induced diabetic rats. Eur. J. Pharm. Biopharm. 76 (2010), 159–169.
122. [122] Christophersen, P., Fanø, M., Saaby, L., Yanga, M., Nielsen, H., Mu, H., Characterization of particulate drug delivery systems for oral delivery of peptide and protein drugs. Curr. Pharm. Des. 21 (2015), 1–18.
123. [123] Lai, S., Wang, Y.-Y., Hanes, J., Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues. Adv. Drug Deliv. Rev. 61:2 (2009), 158–171.
124. [124] Boegh, M., García-Díaz, M., Müllertz, A., Nielsen, H., Steric and interactive barrier properties of intestinal mucus elucidated by particle diffusion and peptide permeation. Eur. J. Pharm. Biopharm. 95 (2015), 136–143.
125. [125] Boegh, M., Nielsen, H., Mucus as a barrier to drug delivery — understanding and mimicking the barrier properties. Basic Clin. Pharmacol. Toxicol. 116 (2015), 179–186.
126. [126] Gullberg, E., Leonard, M., Karlsson, J., Hopkins, A., Brayden, D., Baird, A., Artursson, P., Expression of specific markers and particle transport in a new human intestinal M-cell model. Biochem. Biophys. Res. Commun. 279 (2000), 808–813.
127. [127] des Rieux, A., Fievez, V., Garinot, M., Schneider, Y.-J., Véronique, P., Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J. Control. Release 116 (2006), 1–27.
128. [128] Ragnarsson, E., Schoultz, I., Gullberg, E., Carlsson, A., Tafazoli, F., Lerm, M., Magnusson, K.-E., Söderholm, J., Artursson, P., Yersinia pseudotuberculosis induces transcytosis of nanoparticles across human intestinal villus epithelium via invasin-dependent macropinocytosis. Lab. Investig. 88 (2008), 1215–1226.
129. [129] Gullberg, E., Keita, A., Salim, S., Andersson, M., Caldwell, K., Söderholm, J., Artursson, P., Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J. Pharmacol. Exp. Ther. 319 (2006), 632–639.
130. [130] Maschmeyer, I., Hasenberg, T., Jaenicke, A., Lindner, M., Lorenz, A., Zech, J.L.-A., Sonntag, F., Hayden, P., Ayehunie, S., Lauster, R., Marx, U., Materne, E.-M., Chip-based human liver–intestine and liver–skin co-cultures — a first step toward systemic repeated dose substance testing in vitro. Eur. J. Pharm. Biopharm. 95 (2015), 77–87.
131. [131] Wickström, C., Davies, J., Eriksen, G., Veerman, E., Carlstedt, I., MUC5B is a major gel-forming, oligomeric mucin from human salivary gland, respiratory tract and endocervix: identification of glycoforms and C-terminal cleavage. Biochem. J. 334 (1998), 685–693.
132. [132] Lai, S., O'Hanlon, D., Harrold, S., Man, S., Wang, Y.-Y., Cone, R., Hanes, J., Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. PNAS 104:15 (2007), 1482–1487.
133. [133] Lehr, C.-M., Poelma, F., Junginger, H., Tukker, J., An estimate of turnover time of intestinal mucus gel layer in the rat in situ loop. Int. J. Pharm. 70 (1991), 235–240.
134. [134] Ensign, L., Cone, R., Hanes, J., Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64 (2012), 557–570.
135. [135] Gruber, P., Longer, M., Robinson, J., Some biological issues in oral, controlled drug delivery. Adv. Drug Deliv. Rev. 1 (1987), 1–18.
136. [136] Groo, A.-C., Lagarce, F., Mucus models to evaluate nanomedicines for diffusion., 19(18), 2014, 1097–1108.
137. [137] Petit, B., Bouchemal, K., Vauthier, C., Djabourov, M., Ponchel, G., The counterbalanced effect of size and surface properties of chitosan-coated poly(isobutylcyanoacrylate) nanoparticles on mucoadhesion due to pluronic F68 addition. Pharm. Res. 29 (2012), 943–952.
138. [138] He, C., Yin, L., Tang, C., Yin, C., Size-dependent absorption mechanism of polymeric nanoparticles for oral delivery of protein drugs. Biomaterials 33 (2012), 8569–8578.
139. [139] Damge, C., Maincent, P., Ubrich, N., Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J. Control. Release 117 (2007), 163–170 (117).
140. [140] Olmsted, S., Padgett, J., Yudin, A., Whaley, K., Moench, T., Cone, R., Diffusion of macromolecules and virus-like particles in human cervical mucus. Biophys. J. 81 (2001), 1930–1937.
141. [141] Sheehan, J., Oates, K., Carlstedt, I., Electron microscopy of cervical, gastric and bronchial mucus glycoproteins. Biochem. J. 239 (1986), 147–153.
142. [142] Dawson, M., Wirtz, D., Hanes, J., Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport. J. Biol. Chem. 278:150 (2003), 50393–50401.
143. [143] Reineke, J., Cho, D., Dingle, Y., Cheifetz, P., Laulicht, B., Lavin, D., Furtado, S., Mathiowitz, E., Can bioadhesive nanoparticles allow for more effective particle uptake from the small intestine?. J. Control. Release 170 (2013), 477–484.
144. [144] Janes, K., Calvo, P., Alonso, M., Polysaccharide colloidal particles as delivery systems for macromolecules. Adv. Drug Deliv. Rev. 47 (2001), 83–97.
145. [145] Socha, M., Sapin, A., Damgé, C., Maincent, P., Influence of polymers ratio on insulin-loaded nanoparticles based on poly-ε-caprolactone and Eudragit® RS for oral administration. Drug Deliv. 16:18 (2009), 430–436.
146. [146] Damge, C., Socha, M., Ubrich, N., Maincent, P., Poly(e-caprolactone)/Eudragit nanoparticles for oral delivery of aspart-insulin in the treatment of diabetes. J. Pharm. Sci. 99 (2010), 879–889.
147. [147] Pan, Y., Zheng, J.-M., Zhao, H.-Y., Li, Y.-J., Xu, H., Gang, W., Relationship between drug effects and particle size of insulin-loaded bioadhesive microspheres. Acta Pharmacol. Sin. 23:111 (2002), 1051–1056.
148. [148] Elsayed, A., Al-Remawi, M., Qinna, N., Farouk, A., Al-Sou'od, K., Badwan, A., Chitosan–sodium lauryl sulfate nanoparticles as a carrier system for the in vivo delivery of oral insulin. AAPS PharmSciTech 12:13 (2011), 958–964.
149. [149] Avadi, M., Sadeghi, A., Mohammadpour, N., Abedin, S., Atyabi, F., Dinarvand, R., Rafiee-Tehrani, M., Preparation and characterization of insulin nanoparticles using chitosan and Arabic gum with ionic gelation method. Nanomed. Nanotechnol. Biol. Med. 6 (2010), 58–63.
150. [150] Kolterman, O., Buse, J., Fineman, M., Gaines, E., Heintz, S., Bicsak, T., Taylor, K., Kim, D., Aisporna, M., Wang, Y., Baron, A., Synthetic Exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J. Clin. Endocrinol. Metabol. 88:17 (2003), 3082–3089.
151. [151] Wang, M., Zhang, Y., Feng, J., Gu, T., Dong, Q., Yang, X., Sun, Y., Wu, Y., Chen, Y., Kong, W., Preparation, characterization, and in vitro and in vivo investigation of chitosan-coated poly(D,L-lactide-co-glycolide) nanoparticles for intestinal delivery of exendin-4. Int. J. Nanomedicine 8 (2013), 1141–1154.
152. [152] Wang, M., Zhang, Y., Sun, B., Sun, Y., Gong, X., Wu, Y., Zhang, X., Kong, W., Chen, Y., Permeability of Exendin-4-loaded chitosan nanoparticles across MDCK cell monolayers and rat small intestine. Biol. Pharm. Bull. 37:15 (2014), 740–747.
153. [153] Zhang, X., Sun, M., Zheng, A., Cao, D., Bi, Y., Sun, J., Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur. J. Pharm. Sci. 45 (2012), 632–638.
154. [154] Li, X., Guo, S., Zhu, C., Zhu, Q., Gan, Y., Rantanen, J., Rahbek, U., Hovgaard, L., Yang, M., Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials 34 (2013), 9678–9687.
155. [155] Ahn, S., Lee, I.-H., Lee, E., Kim, H., Kim, Y.-C., Jon, S., Oral delivery of an anti-diabetic peptide drug via conjugation and complexation with low molecular weight chitosan. J. Control. Release 170 (2013), 226–232.
156. [156] Zhang, Y., Wua, X., Menga, L., Zhanga, Y., Ai, R., Qi, N., He, H., Xua, H., Tang, X., Thiolated Eudragit nanoparticles for oral insulin delivery: preparation, characterization and in vivo evaluation. Int. J. Pharm. 436 (2012), 341–350.
157. [157] Zhang, J., Zhu, X., Jin, Y., Shan, W., Huang, Y., Mechanism study of cellular uptake and tight junction opening mediated by goblet cell-specific trimethyl chitosan nanoparticles. Mol. Pharm. 11 (2014), 1520–1532.
158. [158] Reis, C., Veiga, F., Ribeiro, A., Neufeld, R., Damge, C., Nanoparticulate biopolymers deliver insulin orally eliciting pharmacological response. J. Pharm. Sci. 97:112 (2008), 5290–5305.
159. [159] Zhang, N., Ping, Q., Huanga, G., Xua, W., Investigation of lectin-modified insulin liposomes as carriers for oral administration. Int. J. Pharm. 294 (2005), 247–259.
160. [160] Zhang, N., Ping, Q., Huang, G., Xu, W., Cheng, Y., Han, X., Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int. J. Pharm. 327 (2006), 153–159 (327 (2006) 153–159).
161. [161] Chalasani, K., Russell-Jones, G., Jain, A., Diwan, P., Jain, S., Effective oral delivery of insulin in animal models using vitamin B12-coated dextran nanoparticles. J. Control. Release 122 (2007), 141–150.
162. [162] Chalasani, K., Russell-Jones, G., Yandrapu, S., Diwan, P., Jain, S., A novel vitamin B12-nanosphere conjugate carrier system for peroral delivery of insulin. J. Control. Release 117 (2007), 421–429.
163. [163] Ke, Z., Guo, H., Zhu, X., Jin, Y., Huang, Y., Efficient peroral delivery of insulin via vitamin B12 modified trimethyl chitosan nanoparticles. J. Pharm. Pharm. Sci. 18:12 (2015), 155–170.
164. [164] Li, X., Wang, C., Liang, R., Sun, F., Shi, Y., Wang, A., Liu, W., Sun, K., Li, Y., The glucose-lowering potential of exenatide delivered orally via goblet cell-targeting nanoparticles. Pharm. Res. 32 (2015), 1017–1027.
165. [165] van der Merwe, S., Verhoef, J., Verheijden, J., Kotze, A., Junginger, H., Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur. J. Pharm. Biopharm. 58 (2004), 225–235.
166. [166] Jin, Y., Song, Y., Zhu, X., Zhou, D., Chen, C., Zhang, Z., Huang, Y., Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33 (2012), 1573–1582.
167. [167] Zhang, X., Qi, J., Lu, Y., He, W., Li, X., Wu, W., Biotinylated liposomes as potential carriers for the oral delivery of insulin. Nanomed. Nanotechnol. Biol. Med. 10 (2014), 167–176.
168. [168] Pridgen, E., Alexis, F., Kuo, T., Levy-Nissenbaum, E., Karnik, R., Transepithelial transport of Fc-targeted nanoparticles. Sci. Transl. Med., 5(1213), 2013, 213ra167.
169. [169] K. Tyner, N. Sadrieh, Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review, chez Characterization of Nanoparticles Intended for Drug Delivery, Method in Molecular Biology, vol. 697, S. McNeil, Éd., Pringer Science Business Media, 2011, pp. 17-31.
170. [170] Sainz, V., Conniot, J., Matos, A., Peres, C., Zupan, E., Moura, L., Silva, L., Florindo, E., Gaspar, R., Regulatory aspects on nanomedicines. Biochem. Biophys. Res. Commun. 468 (2015), 504–510.
171. [171] EMEA, Reflection Paper on Nanotechnology-based Medicinal Products for Human Use. 2006.
172. [172] FDA, Nanotechnology Task Force — A Report of the U.S. Food and Drug Administration. 2007.
173. [173] AFSSAPS, Recommendations for Toxicological Evaluation of Nanoparticle Medicinal Products. 2011.
174. [174] ETPN, White Paper to the Horizon 2020 Framework Programme for Research and Innovation — Recommendations from the Nanomedicine Community. 2013.
175. [175] Karnik, R., Gu, F., Basto, P., Cannizzaro, C., Microfluidic platform for controlled synthesis of polymeric nanoparticles. Nano Lett. 8:9 (2008), 2906–2912.
176. [176] Lim, J.-M., Bertrand, N., Valencia, P., Rhee, M., Langer, R., Jon, S., Farokhzad, O., Karnik, R., Parallel microfluidic synthesis of size-tunable polymeric nanoparticles using 3D flow focusing towards in vivo study. Nanomed. Nanotechnol. Biol. Med. 10 (2014), 401–409.
177. [177] Zhao, C.-X., Multiphase flow microfluidics for the production of single or multiple emulsions for drug delivery. Adv. Drug Deliv. Rev. 65 (2013), 1420–1446.
178. [178] Pessi, J., Santos, H., Miroshnyk, I., Yliruusi, J., Weitz, D., Mirza, S., Microfluidics-assisted engineering of polymeric microcapsules with high encapsulation efficiency for protein drug delivery. Int. J. Pharm. 472 (2014), 82–87.
179. [179] Mandpe, L., Pokharkar, V., Quality by design approach to understand the process of optimization of iloperidone nanostructured lipid carriers for oral bioavailability enhancement. Pharm. Dev. Technol. 20:13 (2015), 320–329.
180. [180] Damge, C., Aprahamian, M., Marchais, H., Benoit, J.-P., Pinget, M., Intestinal absorption of PLAGA microspheres in the rat. J. Anat. 189:13 (1996), 491–501.
181. [181] Limpanussorn, J., Simon, L., Dayan, D., Transepithelial transport of large particles in rat: a new model for the quantitative study of particle uptake. J. Pharm. Pharmacol. 50 (1998), 753–760.
182. [182] Jani, P., Halbert, G., Langridge, J., Florence, A., The uptake and translocation of latex nanospheres and microspheres after oral administration to rats. J. Pharm. Pharmacol. 41 (1989), 809–812.
183. [183] Lin, P.-C., Lin, S., Wang, P., Sridhar, R., Techniques for physicochemical characterization of nanomaterials. Biotechnol. Adv. 32 (2014), 711–726.
184. [184] Brown, S., Boyko, V., Meyers, G., Voetz, M., Wohlleben, W., Toward advancing nano-object count metrology: a best practice framework. Environ. Health Perspect. 121:111-12 (2013), 1282–1291.
185. [185] Jones, C., Grainger, D., In vitro assessments of nanomaterial toxicity. Adv. Drug Deliv. Rev. 61 (2009), 438–456.
186. [186] Schuster, B., Suk, J., Woodworth, G., Hanes, J., Nanoparticle diffusion in respiratory mucus from humans without lung disease. Biomaterials 34:113 (2013), 3439–3446.
187. [187] Starostina, N., West, P., Atomic force microscopy in the characterisation of drug nanoparticles. Innov. Pharm. Technol., 2006, 74–77.
188. [188] Bell, N., Minelli, C., Tompkins, J., Stevens, M., Shard, A., Emerging techniques for submicrometer particle sizing applied to Stöber silica. Langmuir 28 (2012), 10860–10872.
189. [189] Sanders, N., De Smedt, S., Van Rompaey, E., Simoens, P., De Baets, F., Demeester, J., Cystic fibrosis sputum: a barrier to the transport of nanospheres. Am. J. Respir. Crit. Care Med. 162 (2000), 1905–1911.
190. [190] Groo, A.-C., Mircheva, K., Bejaud, J., Ailhas, C., Panaiotov, I., Saulnier, P., Ivanova, T., Lagarce, F., Development of 2D and 3D mucus models and their interactions with mucus-penetrating paclitaxel-loaded lipid nanocapsules. Pharm. Res. 31 (2014), 1753–1765.
191. [191] Lieleg, O., Vladescu, I., Ribbeck, K., Characterization of particle translocation through mucin hydrogels. Biophys. J. 98 (2010), 1782–1789 (Volume 98 May 2010 1782–1789).
192. [192] Boegh, M., Baldursdóttir, S., Müllertz, A., Nielsen, H., Property profiling of biosimilar mucus in a novel mucus-containing in vitro model for assessment of intestinal drug absorption. Eur. J. Pharm. Biopharm. 87 (2014), 227–235.
193. [193] Abdulkarim, M., Agulló, N., Cattoz, B., Griffiths, P., Bernkop-Schnürch, A., Nanoparticle diffusion within intestinal mucus: three-dimensional response analysis dissecting the impact of particle surface charge, size and heterogeneity across polyelectrolyte, pegylated and viral particles. Eur. J. Pharm. Biopharm. 97 (2015), 230–238.
194. [194] Suh, J., Dawson, M., Hanes, J., Real-time multiple-particle tracking: applications to drug and gene delivery. Adv. Drug Deliv. Rev. 57 (2005), 63–78.
195. [195] Hunter, A., Elsomb, J., Wibroec, P., Moghimi, S., Polymeric particulate technologies for oral drug delivery and targeting: a pathophysiological perspective. Nanomedicine: Nanotech Biol Med 8 (2012), S5–20.
196. [196] Hirsch, I., Insulin analogues. N. Engl. J. Med. 352 (2005), 174–183.
197. [197] Heinemann, L., Jacques, Y., Oral insulin and buccal insulin: a critical reappraisal. J. Diabetes Sci. Technol. 3:13 (2009), 568–584.
198. [198] Iyer, H., Khedkar, A., Verma, M., Oral insulin — a review of current status. Diabetes Obes. Metab. 12 (2010), 179–185.
199. [199] Kidron, M., Dinh, S., Menachem, Y., Abbas, R., Variano, B., Goldberg, M., Arbit, E., Bar-On, H., A novel per-oral insulin formulation: proof of concept study in non-diabetic subjects. Diabet. Med. 21 (2004), 354–357.
200. [200] Luzio, S., Dunseath, G., Lockett, A., Broke-Smith, T., New, R., Owens, D., The glucose lowering effect of an oral insulin (Capsulin) drring an isoglycaemic clamp study in persons with type 2 diabetes. Diabetes Obes. Metab. 12 (2010), 82–87.
201. [201] Eldor, R., Arbit, E., Corcos, A., Kidron, M., Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One, 8(4), 2013, e59524.
202. [202] Beglinger, C., Poller, B., Arbit, E., Ganzoni, C., Gass, S., Gomez-Orellana, I., Drewe, J., Pharmacokinetics and pharmacodynamic effects of oral GLP-1 and PYY3-36: a proof-of-concept study in healthy subjects. Clin. Pharmacol. Ther. 84:14 (2008), 466–474.
203. [203] Steinert, R., Poller, B., Castelli, M., Friedman, K., Huber, A., Drewe, J., Beglinger, C., Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects. Clin. Pharmacol. Ther. 86:16 (2009), 644–650.
204. [204] Steinert, R., Poller, B., Castelli, C., Drewe, J., Berlinger, C., Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects. Am. J. Nutr. 92 (2010), 810–817.
205. [205] Eldor, R., Kidron, M., Arbit, E., A single-blind, two period study to assess the safety and pharmacodynamics of an orally delivered GLP-1 analog (exenatide) in healthy subjects. chez American Diabetes Association — 70th Scientific Sessions, Orlando, 2010.
206. [206] Morçol, T., Bell, S., Method for Processing Milk. (US Brevet US 6,183,803 B1), 6th February 2001.
207. [207] Debrouse, D., Microencapsulated Bioactive Agents for Oral Delivery and Methods of Use Thereof. (EU Brevet EP 2,403,447 A4), 2014.
208. [208] Nowotnik, D., Zarzycki, R., Sood, P., Ummaneni, N., Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes. (US Brevet 0,231,069 A1, 13th September 2012.
209. [209] Himes, S., Luke, M., Nanostructures Suitable for Delivery of Agents. (WO Brevet 065181 A1), 2009.
210. [210] Lee, W., Lu, F., Therapeutic Calcium Phosphate Particles and Method of Making and Using Same. (US Brevet 0,128,767 A1), 24th May 2012.
211. [211] Tu, H., Sung, H., A Pharmaceutical Composition of Nanoparticles. (WO Brevet 133198 A1), 2011.
212. [212] Perera, G., Greindl, M., Palmberger, T., Bernkop-Schnürch, A., Insulin-loaded poly(acrylic acid)-cysteine nanoparticles: stability studies towards digestive enzymes of the intestine. Drug Deliv. 16:15 (2009), 254–260.
213. [213] Deutel, B., Greindl, M., Thaurer, M., Bernkop-Schnürch, A., Novel insulin thiomer nanoparticles: in vivo evaluation of an oral drug delivery system. Biomacromolecules 9 (2008), 278–285.
214. [214] Hoffer, M., Use of Compounds Containing Thiol Groups as an Efflux Pump Inhibitor. (EU Brevet 1,768,676 A1), 2007.
215. [215] Lau, J., Geho, B., Orally Bioavailable Lipid-based Constructs. (US Brevet 8,962,015 B2), 24th February 2015.
216. [216] Chen, H., Langer, R., Polymerized Liposomes Targeted to M Cells and Useful for Oral or Mucosal Drug Delivery. (US Brevet 6,060,082), 9th May 2000.
217. [217] New, R., Langridge, J., Smith, C., Pharmaceutical Compositions Containing Insulin. (US Brevet 0,115,592 A1), 2002.
218. [218] Vol, A., Gribova, O., Melamed, D., Method and Composition for Oral Administration of Insulin. (WO Brevet 087634 A2), 16th July 2009.
219. [219] Olya, S., Khorvash, M., Rahmani, H., Esmaeilkhanian, S., Olya, B., Sadri, H., Oral delivery of insulin-loaded nanoparticles in diabetic rabbits and in sheep. Czech J. Anim. Sci. 59:16 (2014), 251–256.
220. [220] Ramachandran, R., Paul, W., Sharma, C., Synthesis and characterization of PEGylated calcium phosphate nanoparticles for oral insulin delivery. J. Biomed. Mater. Res. B Appl. Biomater. 88B (2009), 41–48.
221. [221] Cui, F.-D., Tao, A.-J., Cun, D.-M., Zhang, L.-Q., Shi, K., Preparation of insulin loaded PLGA-Hp55 nanoparticles for oral delivery. J. Pharm. Sci. 96 (2007), 421–427.
222. [222] Wu, Z., Ling, L., Zhou, L., Guo, X., Jiang, W., Qian, Y., Luo, K., Zhang, L., Novel preparation of PLGA/HP55 nanoparticles for oral insulin delivery. Nanoscale Res. Lett., 7(1), 2012, 299.